Bernards Rene 4
4 · LIXTE BIOTECHNOLOGY HOLDINGS, INC. · Filed Jul 5, 2024
Insider Transaction Report
Form 4
Bernards Rene
Director
Transactions
- Award
Options to Purchase Common Stock
2024-06-30+10,000→ 10,000 totalExercise: $2.37From: 2024-06-30Exp: 2029-06-30→ Common (10,000 underlying) - Award
Options to Purchase Common Stock
2024-06-30+4,149→ 4,149 totalExercise: $2.37From: 2024-06-30Exp: 2029-06-30→ Common (4,149 underlying)
Footnotes (2)
- [F1]Effective June 30,2024, the reporting person was granted stock options to purchase an aggregate of 10,000 shares, vesting on the last day of each subsequent quarter until fully vested (i.e. vesting to start on September 30,2024). The grant was (a) in lieu of cash compensation to which the reporting person was otherwise entitled to receive under his previous agreement with the Company which has been amended as July 3,2024 to provide for the grant of stock options to replace the payment of cash; and (b) pursuant to the annual grant under the Company's amended Compensation Plan applicable to the Company's non-officer directors.
- [F2]Effective June 30, 2024, the reporting person was granted stock options to purchase an aggregate of 4,149 shares vesting immediately. The grant was (a) in lieu of cash compensation due to the reporting person pursuant to his previous agreement with the Company referenced in Footnote 1; and (b) pursuant to the quarterly grant under the Company's amended Compensation Plan applicable to the Company's non-officer directors.